GENAISSANCE: Der Inbegriff der Zukunft zum Dumpingpreis - 500 Beiträge pro Seite

[Neoe]

Genaissance(Nasdaq-NM:GNSC) ist ein Pharmacogenomics-Unternehmen ;heißt, sie versuchen Medikamente auf die persönliche Verträglichkeit abzustimmen , indem sie die genetische Ursache von Nebenwirkungen aufdecken und so gezielt sagen können , wer welches Medikament verträgt.

Die unglaublichen Facts:

Cash:50 Mio $
Total assets:79 Mio $
Marktkap.:42 Mio $ !!!!!!!!!!!
Shares out: 23 Mio.
Share price:1,65 $

Die großen der Pharmabranche sind bereits Feuer und Flamme. Die Absatzzahlen für bestehende Medikamente könnten sich anscheinend verzehnfachen und das Risiko, daß ein Medikament wegen unerwünschter Nebenwirkungen in Einzelfällen nicht zugelassen wird ,verringert sich erheblich , da die Nebenwirkungen mit bestimmten genetischen Vorraussetzungen in Verbindung gebracht werden können. Anstatt gleich das gesamte Medikament zu kippen , werden zukünftig die nicht geeigneten Patienten herausgefiltert.

Kundenliste gefällig (steht im Q1-Report auch nochmal):

Pharmas:
ASTRA ZENECA
PFIZER
JOHNSON&JOHNSON

Biotech:
BIOGEN

Der folgende Quartalsbericht sollte alle Fragen beantworten.
Leßt ihn euch aufmerksam durch , einzig negativ ist die Cashburnrate. Aber die Kohle wird bis zum break even reichen.





Genaissance Pharmaceuticals Reports First Quarter Results

Quarter Highlighted by Commercial Progress, Significant Reduction
In Operating Expenses, and Strong Data From STRENGTH I Trial

NEW HAVEN, Conn., April 26 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC) today reported its financial results for the first quarter ended March 31, 2002.

For the three months ended March 31, 2002, revenues were $1.9 million, compared to $1.0 million for the first quarter last year. Operating expenses for the quarter were $10.7 million, of which $8.2 million were attributable to research and development. This compares to operating expenses of $13.0 million and research and development expenses of $9.9 million for the first quarter of 2001. The Company reported a net loss for the quarter of $9.1 million or $0.40 per share, compared to a net loss of $11.2 million or $0.49 per share for the same period last year.

Operating expenses decreased significantly from $15.0 million in the fourth quarter of 2001 to $10.7 million in the first quarter of 2002, a decrease of nearly 30 percent. This decrease reflects the completion of patient recruitment and associated costs from the STRENGTH trials as well as a continuance of reduced spending levels now that the Company`s infrastructure is fully in place. The Company believes that its business model is scalable and its current cost structure will support its planned revenue increases for 2002.

As of March 31, 2002, the Company had cash, cash equivalents and marketable securities totaling $50.1 million.

"Our first quarter results reflect our heightened efforts toward commercializing our technology, while prudently managing our financial resources," said Gualberto Ruano, M.D., Ph.D., Chief Executive Officer of Genaissance. "We gained momentum in the commercial arena with a breakthrough agreement with Biogen and, with our ongoing analysis of the STRENGTH data, we are discovering HAP(TM) Markers which we believe will have important commercial value to the growing cholesterol management market."

Highlights of the quarter include:

-- Genaissance signed an agreement with Biogen, one of the world`s
premiere biotechnology companies, in which Genaissance`s HAP(TM)
Technology will be applied to drugs currently in Biogen`s product
pipeline and to drug targets under investigation. This is the first
time Genaissance`s technology will be used on a product already in
clinical development and is the first time that the technology will be
used to pair a pharmaco-genomics test with a drug for use in marketing.
The Company believes this collaboration represents a new marketing
paradigm and sets the tone for further drug specific collaborations.

-- Ongoing analyses of the STRENGTH I Study further demonstrated the
ability of HAP(TM) Technology to identify genetic markers that are
associated with the effects of statin therapy. Of the HAP(TM) Markers
examined so far, 25 were linked to drug-specific clinical responses for
simvastatin (Zocor(R)(1)), atorvastatin (Lipitor(R)(2)) or pravastatin
(Pravachol(R)(3)). The Company believes these important findings
strengthen the commercial value of its HAP(TM) Markers for the
development of pharmaceutical and diagnostic products.

-- Genaissance launched the CARING (Clozapine and Agranulocytosis
Relationships Investigated by Genetics (HAP(TM) Markers)) Study during
the quarter, which is designed to discover genomic markers for
identifying patients at risk of clozapine-induced agranulocytosis, a
potentially life-threatening depletion of white blood cells. Clozapine
is a highly effective treatment for schizophrenia but its use is
limited, in part, because of the risk of agranulocytosis and the
requirement for those on the drug to undergo repeated blood monitoring.
By discovering HAP(TM) Markers that predict which individuals will be
at risk of developing agranulocytosis, Genaissance hopes to reduce or
eliminate the need for blood monitoring so that its HAP(TM)-Clozapine
will be of benefit to more patients and, therefore, more widely
prescribed.

-- Realizing the importance and breadth of the Japanese market,
Genaissance signed an agreement with INTEC W&G Corporation, a leading
Japanese bioinformatics and advanced research business, to market
Genaissance`s proprietary pharmacogenomics applications and products to
pharmaceutical, biotechnology and diagnostic companies located in
Japan. Japan is the second largest pharmaceutical market in the world
and is home to nearly 600 biopharmaceutical companies.


With respect to the full year 2002, the Company reiterates its prior revenue guidance and issues the following reduced operating expense and cash usage projections:

-- Revenues for the year to be between $10 and $15 million
-- R&D spending for the year to be between $30 and $32 million
-- SG&A spending for the year to be between $10 and $11 million
-- Projected net loss for the year to be between $30 and $33 million
-- Cash usage for the year to be between $30 and $33 million


"We are pleased by the variety of deals that we have completed utilizing Genaissance`s pharmacogenomics content and continue to see an increase in our business development activities," said Kevin Rakin, President and Chief Financial Officer of Genaissance. "With an established infrastructure and a growing acceptance of the value of pharmacogenomics, Genaissance is able to aggressively pursue high value business opportunities. Therefore, we anticipate our burn rate decreasing to a target of $20 million for the remaining three quarters of the year."


Genaissance Pharmaceuticals, Inc. is the world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company markets its technology and clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. The Company also has identified candidates for development in its own pipeline of products utilizing its proprietary genetic markers. Genaissance has agreements with three of the top five pharmaceutical companies as well as one of the premier biopharmaceutical companies: AstraZeneca, Biogen, Johnson & Johnson and Pfizer. Genaissance is located in Science Park in New Haven, Connecticut. Please visit http://www.genaissance.com for additional information.

[ZittrigeHand]

@ neoe
hast post

[Neoe]

Manipulation hoch 100. Was bei diesem Stock abgeht ist unglaublich. Irgendwas kommt da und ich denke es wird was gutes sein. Man schaue sich mal die time&sales von heute an, nach diesem Schema läuft das schon Tage. Mit 100er Trades wird die Aktie abgeschossen und irgendwann kommen dann riesege Blocktrades. Selber schuld wer nicht merkt was im hier entgeht.
Morgen ist übrigens eine Konferenz.

Senior Executives from Genaissance Pharmaceuticals, Inc., GenVec and Other Companies Will Present to Investors at Biotech/Genomics Stocks Forum
The Forum, to be Held May 11, Will Provide Investors the Opportunity to Hear Analyst-Style Presentations and Question Company Executives Directly by Attending Onsite or Online
RICHMOND, Va., April 30, 2002 (PRIMEZONE) -- A Biotech/Genomics Stocks Forum featuring five companies and an industry expert will be held on May 11. The event is open to the public and will take place at the Sheraton Suites in Alexandria, Virginia and online at www.informedinvestors.com. By attending this Forum, investors can hear directly from company executives and get their investment information straight from the source.

The event, produced by Informed Investors, will take place from 8 a.m. to 12 p.m. Information and registration are available at www.informedinvestors.com or by calling 888-301-6618.

Current and potential investors will hear from Biotech and Genomics sector companies including Genaissance Pharmaceuticals, Inc. (Nasdaq:GNSC) and GenVec (Nasdaq:GNVC). Executives from each company will give 20 minute analyst-style presentations, and a 5-10 minute question and answer session with the investor audience follows each presentation.

The keynote address will be delivered by Dennis E. Ohman, Ph.D. Dr. Ohman is the Chair of the Microbiology & Immunology Department at the Medical College of Virginia Campus of Virginia Commonwealth University. The department is highly research oriented, with a focus on cell and molecular biology, molecular genetics, and immunology. Dr. Ohman also serves as a Research Microbiologist at McGuire Medical Center.

Genaissance Pharmaceuticals, Inc. is the world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company discovers genetic markers (haplotypes) that are predictive of drug efficacy and safety, and markets its haplotype technology and its clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. The Company is also developing its own internal pipeline of products utilizing its proprietary genetic markers. Genaissance has agreements with three of the top ten pharmaceutical companies: Pfizer, AstraZeneca and Johnson & Johnson. Genaissance is located in Science Park in New Haven, Connecticut. They will be represented by Mr. Kevin Rakin, President and Chief Financial Officer at their 9:45 presentation.

GenVec will be speaking to investors at 11:30. GenVec develops gene-based products that cause the production of therapeutic proteins at the site of disease. GenVec`s current areas of focus are cardiovascular disease, oncology and ophthalmology. GenVec`s product candidates are comprised of genes and gene transfer systems that transport those genes into cells at the site of the disease.

Informed Investors is the leading producer of online and offline industry-specific investment conferences for individual investors and a member of the WILink family of companies serving self-reliant investors.

About WILink: Since 1992, WILink (www.wilink.com) has opened information channels between public companies and potential investors. WILink is an investor relations and investment services group that markets a range of services that help publicly traded companies and mutual funds attract and retain well informed investors, while providing investors with access to information to make well informed investment decisions. This year WILink will make more than 7 million investor introductions to over 4,200 corporate clients through services including The Annual Reports Service, The Fund Info Service, Vcall (www.vcall.com) Investor Conference (www.investorconference.com) and Informed Investors Forums (www.informedinvestors.com). These services provide investors free access to onsite and webcast investor events and company financial reports through WILink`s relationships with over 220 leading financial media channels in 14 countries including The Wall Street Journal, Financial Times, Barron`s and Yahoo!Finance. For companies and mutual funds, these services enable compliance with regulation fair-disclosure requirements and provide visibility with investors at the precise point investors are making decisions. WILink, Inc., a wholly owned subsidiary of WILink.com plc (WLK on The London Stock Exchange), began operations in Richmond, Va. in 1993.

[belina]

Hi, klingt interessant! Aus welchen Quellen kommen den die
Infos, wo gibts den Chart?

[Neoe]

belina@:
Für die Infos mußt du nicht einmal lange suchen. Auf www.nasdaq.com findest du den letzten Quartalsbericht , der hier ja schon drin ist , weiter kannst du dich dort auch von der lächerlichen Marktkapitalisierung überzeugen.

Die Investorenkonferenz geht gerade los und man kann sie unter www.informedinvestors.com mitverfolgen. Unter uns befinden sich auch noch genug andere , zu unrecht geschundene Brüder.....

[Neoe]

Wichtigste Aussagen:
Geld reicht nach dem Stand von 1.April 02 noch acht weitere Quartale , also bis 1.April 04 , cashburn pro Quartal soll dabei 2003 HÖCHSTENS noch bei 6 Millionen liegen.
Zudem wurde gesagt, daß man mit Johnson&Johnson und Biogen bereits im ersten Quartal 2004 fertige Medikamente im Angebot haben möchte.
Jetzt kann sich jeder selbst ausrechnen , wie es weiter gehen wird. Ich denke das der Verlust auch bis Ende 2003 nicht mehr allzu groß sein wird , da bei erreichen von Meilensteinen gerade aus der Kasse von Biogen , die ja erst seit kurzem mit GNSC zusammenarbeiten , einiges an Geld fließen soll und einige andere "blue chip"-Partner geködert werden sollen.

Und für den, den es interessiert , macht euch mal hier etwas zu schaffen. Scheint als wäre die Tafel zum Anstieg eigentlich schon längst angerichtet.......:
http://iw.thomsonfn.com/iwatch/cgi-bin/iw_ticker?ticker=gnsc…

[Neoe]

Da mein Thread die Höchststrafe erleidet , nämlich Ignoranz , gehe ich davon aus , daß irgendwas mit meinem Investment nicht stimmen kann. Ich kann leider weit und breit nicht erkennen was , vielleicht klärt mich ja einer auf?

[kalabrienfan]

Hallo Neoe,
ich bin seit längerem investiert und habe jetzt nochmal
nachgekauft.
Das ist keine Zockeraktie, sondern eine Langfristanlage.
Damit kann man nicht auf die Schnelle viel Geld verdienen
und deshalb interessiert sich kaum jemand dafür.
Ich finde das gut so, denn wenn die Empfehlungen auch
in Deutschland kommen ( Förtsch und Konsorten )ist es
für mich sowieso an der Zeit, meine Anteile zu verkaufen.
So bin ich eigentlich die letzten 2 Jahre einigermaßen gut
über die Runden gekommen.
Die Cashburnrate ist natürlich wahnsinnig hoch. Ich schätze
mal, die werden früher oder später geschluckt, was unser
Schaden nicht sein dürfte. Daß die Technologie genial ist,
wenn es denn wirklich funktioniert, steht außer Frage.
Viele Grüße

[Neoe]

kalabrienfan@:
Ich hab schon gedacht , daß man hier mit Qualität gar nicht mehr landen kann. Wenigstens mal ein Mitstreiter. Aber eigentlich müßte diese Aktie recht "trendy" sein. Da GLAXOSMITHKLINE im untenstehenden Artikel ja sogar sagt , daß die Pharmas eigentlich noch gar nicht realisiert haben , um was für eine riesige Sache es sich hier handelt , kann man dem WO-Board eigentlich nicht böse sein.
Bis auf die Tatsache , daß Glaxo hier als Marktführer angesehen wird , finde ich den Artikel ganz gut. Glaxo ist nämlich de facto nicht so weit wie DNAP und GNSC , aber das wissen sie selbst am Besten.


Targeted Therapy Makes a Stand


By Malorye Branca
Bio-IT World

BOSTON (05/07/02)—A series of study results and a new stance by the Food and Drug Administration may provide badly needed fuel for pharmacogenomics. The study of why individuals respond differently to drugs — pharmacogenomics — is one of the most potentially exciting applications of the Human Genome Project. In the not-too-distant future, doctors will be able to use patients` unique genetic profiles to guide treatment decisions, and medicines will be tailored to genetic makeup.

But despite widespread anticipation of the promise of pharmacogenomics, surprisingly few findings to date have supported this view. "There was a big wave of investment in this field awhile ago, and people found it was harder to get results than they thought," says Dennis Henner of MPM Capital.

As a result, the field is losing steam. Some of the smaller pioneering pharmacogenomics companies are anxious to reverse that trend.

Researchers at Genaissance Pharmaceuticals, based in New Haven, Conn., recently reported "statistically significant" relationships between genetic markers and patient responses to cholesterol-lowering drugs, called statins. If confirmed, these relationships could lead to pharmacogenetic tests to determine which drug will work best in a particular patient.

"Number one, it [the study] validates what we are doing, and that we can identify these variations that predict response to therapeutic agents," says Dr. Carol Reed, executive director of medical affairs at Genaissance. "Secondly, the associations are significant."

"Genaissance does not sell any of these drugs, and they are the most successful category of drugs in pharmaceutical history," says Peter Tollman of the Boston Consulting Group. "If these associations are significant enough, this could create a very interesting dynamic. We will see a whole new set of competitors going after the Big Pharma drugs, and a need to respond by Big Pharma."

These results come from an initial analysis of the company`s STRENGTH I (Statin Response Examined by Genetic HAP Markers) study, which involved simvastatin (Merck & Co.`s Zocor); atorvastatin (Pfizer`s Lipitor); and pravastatin (Bristol-Myers Squibb`s Pravachol). The study originally also involved cerivastatin (Bayer`s Baycol), but Genaissance discontinued the Baycol arm of the study when that drug was voluntarily withdrawn from the market last summer after some patients taking it developed potentially fatal side effects. A second study, STRENGTH II, is also nearing completion. It includes the three drugs left in STRENGTH I, as well as lovastatin (Merck`s Mevacor).

The statins represent a huge market. According to IMS Health, Lipitor and Zocor were the second and third top-selling drugs in the world in 2000. IMS recorded almost $16 billion in worldwide sales for cholesterol- and triglyceride-lowering drugs that year.

Statin therapy aims to reduce blood levels of LDL (bad) cholesterol and to improve the ratio of HDL (good) cholesterol to bad. Genaissance has been looking for links between genetic markers and changes in the levels of cholesterol and triglycerides in patients taking these drugs.

Genaissance uses sequencing to find genetic variations called single nucleotide polymorphisms (SNPs) in human DNA. This requires many samples, from the right mix of people, to get a good representation of a target population. The company applies proprietary algorithms to find sets of SNPs, called haplotypes, which are inherited. The goal is to find haplotypes that are "red flags" of disease susceptibility or drug response.

Studying haplotypes, rather than individual SNPs, reduces the number of patients needed for these types of trials because combinations of markers provide a stronger signature than single markers. Genaissance has compiled a database of more than 5,000 such haplotypes, which they call HAP markers. The company has also identified 100 genes that may be linked to patient response to statins.

If further testing confirms the study results, it could lead to products for Genaissance and to better treatment for patients. Tollman, however, advises caution. "The study is small and has other limitations," he says.

In STRENGTH I about 150 patients received each particular type of statin. Overall, more than 500 patients were enrolled. Analysts and researchers are waiting for more details before deciding the study`s importance.

Signs of Hope for Pharmacogenomics?

New studies suggest genetic tests can predict who will do best on therapy using these major drugs. For example, DNAPrint Genomics` study indicated which patients would respond best to Taxol.

Drug Studied/Indication
Source of study
Reference/Date


Estrogen replacement therapy/High cholesterol (cardiovascular disease)
Wake Forest University School of Medicine
New England Journal of Medicine, March 28, 2002


Taxol/Ovarian cancer
DNAPrint Genomics and the University of Miami (Fla.)
Presented at the Society of Gynecological Oncology, March 19, 2002


Statins (Lipitor, Pravachol, Zocor)/High cholesterol
Genaissance Pharmaceuticals
Press release at www.genaissance.com, March 26, 2002


Ziagen/AIDS
Royal Perth Hospital and Murdoch University, Perth, Australia
The Lancet, March 2, 2002

GlaxoSmithKline The Lancet, March 30, 2002



"We did the press release to let the clinical world and investor world know that the study is complete, and that we are analyzing the data, and that there is interesting data there," says Reed, adding that the company plans to publish and present findings from the study throughout the year. (The first presentation was planned for late April, after this issue went to press.) "The study was big enough for us to derive statistically relevant correlations. We expect to derive commercial value from these associations."




FDA`s Positive Position
Perhaps the biggest hurdle to pharmacogenomics has been the perception that the FDA would resist the introduction of these tests. "The FDA never actually said this, but many people believed that the FDA would never allow these types of tests to be approved," says Allen Roses, senior vice president of genetic research at GlaxoSmithKline (GSK), which is a leading player in this field.

But a timely new announcement from the FDA may clear up that perception. "Now the FDA has come out and said, quite dramatically, `Yes, we will look at this,`" says Roses, referring to a recent article in The Pharmacogenomics Journal by Lawrence J. Lesko and Janet Woodcock, two FDA officials. Lesko and Woodcock reported that the FDA has received more than 15 recent applications involving pharmacogenomic tests, and that it is taking steps "to assure that, as a regulatory agency, FDA is prepared to deal with the future influx of [pharmacogenomic data]."

Genaissance`s Reed agrees with Roses about the impact of the article. "This could really change things," she says. With the FDA`s go-ahead, more companies may enter the field, and smaller companies may have less difficulty convincing partners and investors that they can succeed.

With the exception of GSK, leading pharmaceutical companies have been slow in carrying out or funding pharmacogenetic studies of drugs that are already on the market. Last year Jurgen Drews, president of Genaissance and a former president of global research at Roche Pharmaceuticals, was quoted in The Wall Street Journal as saying that pharmaceutical companies were afraid of discovering "the limitations of their drugs."

If pharmacogenetic tests can cause doctors to change prescribing practices, it could erode some drugs` market shares. But it is hard to tell what is keeping Big Pharma away. "I don`t think big companies are trying to delay the development of these tests," says Henner. "The technology just hasn`t yet moved to a point where they see the value of it."

Large pharmas and genomics firms have shown greater interest in applying pharmacogenomics to early-stage drug candidates. By finding out early on that a potential drug has serious side effects in some patients, or by identifying therapies that only work well in a subgroup of people, companies can save on drug development costs. Later, companies may market the therapies and the tests used with them together.

In the meantime, investors may have already grown weary of waiting for results. "Before pharmacogenomics can come into widespread use, these companies will have to show that the data they provide will make a difference to patients, and that doctors can actually use it," say Henner. "Meanwhile, there are a lot of other biotech products that are going to happen much sooner, so that`s where the money is going."




Tide Turning?
During the last few months, there has been a small, but noticeable trickle of results from pharmacogenetic studies (see table). The next step must be to turn these results into actual products.

Early pharmacogenetic tests "looked at extreme responses," says Tony Frudakis, CEO of pharmacogenomics startup DNAPrint Genomics of Sarasota, Fla. "They have looked at too few genes and too few sites in those genes to be useful for more than a very few patients." To become clinically accepted, tests need to work across a wide range of patients. "We are close to this, and Genaissance is close," he says.

DNAPrint recently announced finding genetic markers linked to patient response to paclitaxel (Bristol-Myers Squibb`s Taxol). The company uses an approach similar to that of Genaissance. It hopes to develop a test that will flag those patients who will not have a good response to the drug in order to redirect them to other therapies.

"The answer now relies on how good your informatics are," says Frudakis. "We`re doing complex genetics now, and there are no algorithms out there to do this. You have to develop them yourself."

Even with powerful algorithms, clinical trials cost money. "The big companies should be funding these kinds of studies and making better tools out of these drugs," says Frudakis. "But addressing the current drugs falls on the shoulders of companies like us and Genaissance." Still, Frudakis remains optimistic. "We are writing an NIH grant right now," he says. "If we can get funding, we might have a product on the market in two to three years."

However, GSK`s Roses is skeptical about whether smaller companies can pay for effective pharmacogenomic studies. "We have made a sizable investment in informatics for this, and we are already doing many different clinical studies all the time," says Roses.

GSK, he says, embraced the field early. "We could see that what is good for the patient is good for us," Roses says. Other large pharmaceutical companies may have been slower to climb onboard, he says, because "big pharmas are not mainly R&D organizations; they are sales and marketing organizations, so the people at the top may not fully understand the potential here."

[ZittrigeHand]

hi
bin auch in GNSC.aus irgendwelchen gründen sind sie letzte
woche ziemlich zerschossen wurden.wie NEOE oben berichtete,
immer in 100 trades abgeschossen,dann dicke trades
hinterher.low war bei 1,36..heute momentan bei 1,96 $.
ein schöner anstieg seit freitag.
das einzige was mich bei GNSC stört ist deren informations-
politik,diese lässt zu wünschen übrig.ansonsten halt ich recht viel von denen,die letzten Q`s um 10 % geschlagen,aus-
reichend cash,gutes geschäftsmodel,sowie gute allianzen.
was mir noch postiv auffiel....kein insider(firmenangehöriger)hat trotz des durchaus katastrophalen
charts der letzten monate verkauft.
wollen mal hoffen das sie ihre STRENGTH I ergebnisse was
besser aufschlüsseln,bzw.ihre info-politik verbessern.

gruß
zitter

[Neoe]

Nicht vergessen ZittrigeHand@:
Wie im Artikel gesagt wird , demnächst kommen auch noch die StrenghtII-Resultate.

[ollihat]

GNSC ist bei dem aktuellen Kurs ein aussichtsreiches Investment!

Für mich unverständlich ist die Herunterstufung der Deutschbanker am 29.4. von strong buy auf market perform.
Hat jemand dafür eine Begründung gelesen?

[ZittrigeHand]

jo..olli
die wollten billig rein...lol
na ja,den downgrade hätten die sich sparen können.aktie ist schon vorher ziemlich unter die räder gekommen.

[Neoe]

Die Deutsche Bank ist bereits in GNSC investiert , daß heißt eigentlich grundsätzlich , daß eine Herabstufung Nachkäufe mit sich bringt. Die schneiden sich sicher nicht ins eigene Fleisch , die Welt der Investmentbänker ist ein einziger Sündenpfuhl , nur so langsam durchschaut das glaub ich jeder.

[Neoe]

Bin wirklich gespannt , was Q3 gebracht hat. Alles was über 1,9 Millionen Dollar an Einnahmen liegt , kommt von Biogen und es wäre ein mehr als gutes Zeichen , zumindest für mich,
wenn die Zusammenarbeit endlich auch was abwirft.


Genaissance Pharmaceuticals, Inc. Invites You to Participate in its Third Quarter 2002 Conference Call

New Haven, CT, November 5, 2002 – In conjunction with the release of its financial results for the third quarter ended September 30, 2002, management of Genaissance Pharmaceuticals (Nasdaq: GNSC), will conduct a conference call:

Tuesday, November 12, 2002
11:00 a.m. Eastern

To participate in this call,
dial: 913-981-5522
confirmation code: 716060
shortly before 11:00 a.m. Eastern

To reserve a line,
please call Rhonda Chiger at Rx Communications Group, LLC
917-322-2569.

A replay of the call will be available from 2:00 p.m. Eastern through midnight Monday, November 18th, 2002. The replay number is 719-457-0820, confirmation code 716060 Genaissance Pharmaceuticals, Inc. is the world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company markets its technology and clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with three of the top five pharmaceutical companies as well as one of the premier biopharmaceutical companies: AstraZeneca, Biogen, Johnson & Johnson and Pfizer. Genaissance is located in Science Park in New Haven, Connecticut.